MA53243A - Compositions comprenant une combinaison de ipilimumab et nivolumab - Google Patents
Compositions comprenant une combinaison de ipilimumab et nivolumabInfo
- Publication number
- MA53243A MA53243A MA053243A MA53243A MA53243A MA 53243 A MA53243 A MA 53243A MA 053243 A MA053243 A MA 053243A MA 53243 A MA53243 A MA 53243A MA 53243 A MA53243 A MA 53243A
- Authority
- MA
- Morocco
- Prior art keywords
- nivolumab
- ipilimumab
- compositions
- combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562149325P | 2015-04-17 | 2015-04-17 | |
US201562265268P | 2015-12-09 | 2015-12-09 | |
US201562269000P | 2015-12-17 | 2015-12-17 | |
US201662303855P | 2016-03-04 | 2016-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53243A true MA53243A (fr) | 2021-06-23 |
Family
ID=55809254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053243A MA53243A (fr) | 2015-04-17 | 2016-04-15 | Compositions comprenant une combinaison de ipilimumab et nivolumab |
Country Status (32)
Country | Link |
---|---|
US (4) | US20160304607A1 (fr) |
EP (2) | EP3738610A1 (fr) |
JP (3) | JP6949718B2 (fr) |
KR (1) | KR20170138477A (fr) |
CN (2) | CN113577264A (fr) |
AU (2) | AU2016249395B2 (fr) |
BR (1) | BR112017021688A2 (fr) |
CA (1) | CA2982839A1 (fr) |
CL (1) | CL2017002636A1 (fr) |
CO (1) | CO2017011536A2 (fr) |
CY (1) | CY1123397T1 (fr) |
DK (1) | DK3283107T3 (fr) |
EA (1) | EA201792273A1 (fr) |
ES (1) | ES2813580T3 (fr) |
HK (1) | HK1247099A1 (fr) |
HR (1) | HRP20201334T1 (fr) |
HU (1) | HUE050894T2 (fr) |
IL (2) | IL255072B (fr) |
LT (1) | LT3283107T (fr) |
MA (1) | MA53243A (fr) |
MX (2) | MX2017013270A (fr) |
MY (1) | MY188749A (fr) |
PE (1) | PE20180394A1 (fr) |
PH (1) | PH12017501774A1 (fr) |
PL (1) | PL3283107T3 (fr) |
PT (1) | PT3283107T (fr) |
RS (1) | RS60753B1 (fr) |
SG (2) | SG10201912035YA (fr) |
SI (1) | SI3283107T1 (fr) |
TN (1) | TN2017000440A1 (fr) |
TW (3) | TW202335681A (fr) |
WO (1) | WO2016168716A1 (fr) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
BR112015025852A2 (pt) | 2013-04-09 | 2017-07-25 | Lixte Biotechnology Inc | as formulações de oxabicicloheptanos e oxabicicloheptenos |
PL3508502T3 (pl) | 2013-09-20 | 2023-07-17 | Bristol-Myers Squibb Company | Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
ME03493B (fr) * | 2014-05-13 | 2020-01-20 | Medimmune Ltd | Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules |
TW202132337A (zh) | 2014-05-28 | 2021-09-01 | 美商艾吉納斯公司 | 抗糖皮質素誘導性tnfr家族相關性受體(gitr)抗體類及使用彼等之方法 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
US11149090B2 (en) | 2014-08-12 | 2021-10-19 | Alligator Bioscience Ab | Combination therapies with anti CD40 antibodies |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
WO2016040880A1 (fr) | 2014-09-13 | 2016-03-17 | Novartis Ag | Thérapies combinées d'inhibiteurs d'alk |
AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
PE20180394A1 (es) | 2015-04-17 | 2018-02-28 | Bristol Myers Squibb Co | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo |
EP3288980B1 (fr) | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Traitement du mélanome pd-l1 positif à l'aide d'un anticorps anti-pd-1 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
MA42447A (fr) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation |
KR20180027576A (ko) * | 2015-07-14 | 2018-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법 |
CN114773475B (zh) | 2015-07-30 | 2024-01-12 | 宏观基因有限公司 | Pd-1结合分子和其使用方法 |
JP6883579B2 (ja) | 2015-08-11 | 2021-06-09 | ウーシー バイオロジクス(ケイマン)インコーポレイテッド | 新規抗pd−1抗体 |
EA201890790A1 (ru) | 2015-09-29 | 2018-10-31 | Селджин Корпорейшн | Связывающие pd-1 белки и способы их применения |
MY189018A (en) | 2015-11-18 | 2022-01-19 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
JP7089470B2 (ja) | 2015-12-02 | 2022-06-22 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
TWI758267B (zh) | 2015-12-14 | 2022-03-21 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
JP7000322B2 (ja) | 2015-12-16 | 2022-02-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗lag3抗体および抗原結合性フラグメント |
US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
CA3020649A1 (fr) | 2016-05-18 | 2017-11-23 | Boehringer Ingelheim International Gmbh | Anticorps anti-pd-1 et anti-lag3 pour le traitement du cancer |
IL292302B2 (en) | 2016-05-20 | 2023-10-01 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating factors in cancer immunotherapy |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
CN109952317A (zh) | 2016-09-19 | 2019-06-28 | 细胞基因公司 | 使用pd-1结合蛋白治疗免疫病症的方法 |
CA3041340A1 (fr) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anticorps anti-ox40, anticorps anti-gitr, et leurs procedes d'utilisation |
MX2019006694A (es) * | 2016-12-08 | 2019-08-21 | Lixte Biotechnology Inc | Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. |
KR102606252B1 (ko) * | 2017-01-09 | 2023-11-23 | 테사로, 인코포레이티드 | 항-pd-1 항체로 암을 치료하는 방법 |
TWI788321B (zh) | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
MA47604A (fr) * | 2017-02-21 | 2020-01-01 | Regeneron Pharma | Anticorps anti-pd-1 pour le traitement du cancer du poumon |
EP3600395A4 (fr) * | 2017-03-23 | 2021-05-05 | The General Hospital Corporation | Blocage de cxcr4/cxcr7 et traitement d'une maladie associée au papillomavirus humain |
BR112019018996A2 (pt) * | 2017-03-29 | 2020-04-14 | Celgene Corp | formulações compreendendo proteínas de ligação de pd-1 e métodos para produzir as mesmas |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
EP3612234B1 (fr) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Polythérapie avec un conjugué anticorps anti-axl-médicament |
WO2018193104A1 (fr) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Polythérapie avec un conjugué anticorps-médicament anti-cd25 |
JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
TN2019000294A1 (en) * | 2017-05-02 | 2021-05-07 | Merck Sharp & Dohme | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
TW201842929A (zh) * | 2017-05-03 | 2018-12-16 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
JP7274426B2 (ja) * | 2017-05-16 | 2023-05-16 | ブリストル-マイヤーズ スクイブ カンパニー | 抗gitrアゴニスト抗体での癌の処置 |
KR20200011447A (ko) * | 2017-05-30 | 2020-02-03 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
MX2019012032A (es) | 2017-05-30 | 2019-10-30 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
US20190135905A1 (en) * | 2017-06-16 | 2019-05-09 | Bristol-Myers Squibb Company | Compositions and methods for treating tauopathies |
SG10201913144TA (en) | 2017-07-11 | 2020-03-30 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
CN111132695A (zh) * | 2017-08-18 | 2020-05-08 | 里珍纳龙药品有限公司 | 分析样品基质中蛋白变异体的成像毛细管等电聚焦 |
BR112020003533A2 (pt) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | anticorpos b7-h4 e métodos de uso dos mesmos |
EP3678700B1 (fr) * | 2017-09-05 | 2024-06-19 | Merck Sharp & Dohme LLC | Composés pour la réduction de la viscosité de formulations biologiques |
AU2018330180A1 (en) | 2017-09-07 | 2020-03-19 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
CN111630069B (zh) * | 2017-10-13 | 2024-05-31 | 勃林格殷格翰国际有限公司 | 针对Thomsen-nouvelle(Tn)抗原的人抗体 |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
AU2018359967A1 (en) * | 2017-11-06 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2019100052A2 (fr) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Anticorps cd137 et anticorps ciblant un antigène tumoral et leurs utilisations |
WO2019108951A1 (fr) * | 2017-12-01 | 2019-06-06 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes d'inhibition des palmitoyltransférases de type dhhc pour le traitement du cancer |
US20210363242A1 (en) * | 2018-01-16 | 2021-11-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
MX2020009037A (es) | 2018-03-02 | 2021-01-08 | Five Prime Therapeutics Inc | Anticuerpos de b7-h4 y métodos para usarlos. |
JP2021520201A (ja) * | 2018-04-04 | 2021-08-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗cd27抗体およびその使用 |
JP2021524449A (ja) | 2018-05-23 | 2021-09-13 | アーデーセー セラピューティクス ソシエテ アノニム | 分子アジュバント |
EP3843718A1 (fr) * | 2018-06-15 | 2021-07-07 | The Board Of Regents Of The University Of Texas System | Méthodes de traitement et de prévention du mélanome avec du s-équol |
CA3117016A1 (fr) * | 2018-10-19 | 2020-04-23 | Bristol-Myers Squibb Company | Polytherapie pour melanome |
KR20210091209A (ko) * | 2018-11-05 | 2021-07-21 | 머크 샤프 앤드 돔 코포레이션 | 암의 치료를 위한 항-tigit 항체의 투여 요법 |
KR20210088640A (ko) * | 2018-11-05 | 2021-07-14 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 항-lag3 항체의 투여 요법 및 항-pd-1 항체와의 조합 요법 |
JP2022512875A (ja) * | 2018-11-06 | 2022-02-07 | ゲンマブ エー/エス | 抗体製剤 |
JP7503056B2 (ja) * | 2018-11-07 | 2024-06-19 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗lag3抗体および抗pd-1抗体の共-製剤 |
EP3876978A4 (fr) | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | Formulations stables d'anticorps du récepteur de mort programmé 1 (mp-1) et leurs méthodes d'utilisation |
US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
CA3129901A1 (fr) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Formulation d'anticorps therapeutique |
EP4008346A4 (fr) * | 2019-07-18 | 2022-10-19 | Delta-Fly Pharma, Inc. | Agent pour accentuer l'effet d'un agent anticancéreux |
GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
KR20220115803A (ko) * | 2019-12-13 | 2022-08-18 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
US20230355757A1 (en) * | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
AU2021213969A1 (en) | 2020-01-30 | 2022-09-01 | ONA Therapeutics S.L. | Combination therapy for treatment of cancer and cancer metastasis |
JP2023515675A (ja) * | 2020-03-05 | 2023-04-13 | メルク・シャープ・アンド・ドーム・エルエルシー | Pd-1アンタゴニスト、ctla4アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
MX2022011050A (es) | 2020-03-06 | 2022-12-15 | Ona Therapeutics S L | Anticuerpos anti-cd36 y su uso para tratar cancer. |
US20230285555A1 (en) * | 2020-04-17 | 2023-09-14 | Dingfu Biotarget, Co., Ltd. | Preparation specifically bound with cd137 and use thereof |
BR112022025721A2 (pt) * | 2020-06-19 | 2023-01-03 | Sinocelltech Ltd | Formulação estável para anticorpo monoclonal anti-pd-1 recombinante |
US20210403568A1 (en) * | 2020-06-29 | 2021-12-30 | Cai Gu Huang | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
US20220031843A1 (en) * | 2020-07-08 | 2022-02-03 | Regeneron Pharmaceuticals, Inc. | Stabilized Formulations Containing Anti-CTLA-4 Antibodies |
EP4008345A1 (fr) * | 2020-12-03 | 2022-06-08 | Hexal AG | Nouvelles formulations pour des anticorps |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
TW202308692A (zh) * | 2021-04-27 | 2023-03-01 | ***聯邦商拜奧卡德聯合股份公司 | 包含帕博利珠單抗(pembrolizumab)的藥學組成物及其用途 |
CA3224018A1 (fr) * | 2021-06-18 | 2022-12-22 | Genzyme Corporation | Formulations d'anticorps anti-tgf-beta et leur utilisation |
EP4355780A1 (fr) * | 2021-06-18 | 2024-04-24 | Alligator Bioscience AB | Nouvelles polythérapies et leurs utilisations |
IL308973A (en) * | 2021-07-02 | 2024-01-01 | Gigagen Inc | ANTI-CTLA-4 binding proteins and methods of using them |
CA3226281A1 (fr) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anticorps anti-cd36 et leur utilisation pour traiter le cancer |
WO2023235847A1 (fr) * | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
WO1998016249A1 (fr) | 1996-10-11 | 1998-04-23 | Bristol-Myers Squibb Company | Methodes d'immunomodulation et compositions associees |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
PT2283867E (pt) | 1999-06-25 | 2014-08-29 | Immunogen Inc | Métodos de tratamento usando conjugados de anticorpo antierbb- maitansinóide |
DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2001014424A2 (fr) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Anticorps contre l'antigene ctla-4 humain et utilisation |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
HUE10161767T1 (hu) | 2002-07-03 | 2019-03-28 | Ono Pharmaceutical Co | Immunpotenciáló kompozíciók, amelyek anti-PD-L1 antitesteket tartalmaznak |
AU2003251906B2 (en) | 2002-07-12 | 2008-12-04 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
WO2004010947A2 (fr) | 2002-07-30 | 2004-02-05 | Bristol-Myers Squibb Company | Anticorps humanises contre le 4-1bb humain |
US7488802B2 (en) | 2002-12-23 | 2009-02-10 | Wyeth | Antibodies against PD-1 |
AU2004253630B2 (en) | 2003-07-02 | 2010-11-25 | Innate Pharma S.A.S. | Methods for the production and cytotoxicity evaluation of KIR2DL NK-receptor antibodies |
HUE033129T2 (en) | 2003-07-24 | 2017-11-28 | Innate Pharma Sa | Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
PL2287195T3 (pl) | 2004-07-01 | 2019-10-31 | Novo Nordisk As | Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii |
EP1835929B8 (fr) | 2005-01-06 | 2016-07-27 | Novo Nordisk A/S | Procédés et traitements combinés anti-kir |
DK1836225T3 (da) | 2005-01-06 | 2012-02-27 | Innate Pharma Sas | Kir-bindingagenser og fremgangsmåde til anvendelse deraf |
CN101325968B (zh) * | 2005-03-08 | 2014-04-23 | 辉瑞产品公司 | 抗ctla-4抗体组合物 |
AU2006220828A1 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Anti-MAdCAM antibody compositions |
PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
CA3151350A1 (fr) | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies |
EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
AU2006301163B2 (en) | 2005-10-14 | 2012-02-23 | Innate Pharma | Compositions and methods for treating proliferative disorders |
EP2007423A2 (fr) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Polythérapie à base d'un anticorps anti-ctla4 |
JP5478261B2 (ja) | 2007-01-11 | 2014-04-23 | ノヴォ ノルディスク アクティーゼルスカブ | 抗kir抗体、製剤、およびその使用 |
JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用 |
PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
DK2175884T3 (en) | 2007-07-12 | 2016-09-26 | Gitr Inc | Combination USING GITR BINDING MOLECULES |
US8268970B2 (en) | 2007-10-01 | 2012-09-18 | Bristol-Myers Squibb Company | Human antibodies that bind mesothelin, and uses thereof |
EA201000910A1 (ru) | 2007-11-30 | 2011-04-29 | Бристоль-Мейерз Сквибб Компани | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения |
EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
AU2009255357A1 (en) * | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Methods for predicting patient response to modulation of the co-stimulatory pathway |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
AU2009319856A1 (en) * | 2008-11-28 | 2010-06-03 | Abbvie Inc. | Stable antibody compositions and methods for stabilizing same |
US8709411B2 (en) | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
WO2011066342A2 (fr) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Inhibition simultanée de pd-l1/pd-l2 |
CA2796571C (fr) | 2010-04-13 | 2019-10-29 | Celldex Therapeutics Inc. | Anticorps qui se lient au cd27 humain et utilisations de ceux-ci |
AR083957A1 (es) | 2010-11-22 | 2013-04-10 | Innate Pharma Sa | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica |
CA2828940C (fr) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combinaison de therapies immunomodulatrices locales et systemiques pour l'amelioration du traitement du cancer |
US9220776B2 (en) * | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
LT2699264T (lt) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
SG10201603962TA (en) | 2011-05-25 | 2016-07-28 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory disorders |
WO2013039954A1 (fr) | 2011-09-14 | 2013-03-21 | Sanofi | Anticorps anti-gitr |
LT2776032T (lt) | 2011-11-09 | 2018-12-10 | Bristol-Myers Squibb Company | Hematologinių piktybinių navikų gydymas anti-cxcr4 antikūnu |
WO2013079174A1 (fr) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anticorps anti-pd-l1 et utilisations associées |
CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
KR101566539B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Th2 세포 전환용 에피토프 및 이의 용도 |
JP2015532587A (ja) * | 2012-06-21 | 2015-11-12 | コンピュゲン エルティーディー. | Lsr抗体およびがんの治療のためのその使用 |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
CA2887027C (fr) * | 2012-10-02 | 2021-11-16 | Bristol-Myers Squibb Company | Combinaison d'anticorps anti-kir et d'anticorps anti-pd-1 pour le traitement du cancer |
WO2014209804A1 (fr) * | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Anticorps bispécifiques |
KR101809151B1 (ko) * | 2013-07-18 | 2017-12-15 | (주)앗코스텍 | 키레놀 또는 희첨 추출물을 포함하는 골다공증 예방, 개선 또는 치료용 조성물 |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
BR112016005408B1 (pt) | 2013-09-13 | 2023-03-21 | Beigene Switzerland Gmbh | Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral |
PL3508502T3 (pl) | 2013-09-20 | 2023-07-17 | Bristol-Myers Squibb Company | Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka |
TW202132337A (zh) | 2014-05-28 | 2021-09-01 | 美商艾吉納斯公司 | 抗糖皮質素誘導性tnfr家族相關性受體(gitr)抗體類及使用彼等之方法 |
EP3998079A1 (fr) | 2014-06-06 | 2022-05-18 | Bristol-Myers Squibb Company | Anticorps dirigés contre le récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs procédés d'utilisation |
PE20180394A1 (es) | 2015-04-17 | 2018-02-28 | Bristol Myers Squibb Co | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo |
-
2016
- 2016-04-15 PE PE2017002204A patent/PE20180394A1/es unknown
- 2016-04-15 SG SG10201912035YA patent/SG10201912035YA/en unknown
- 2016-04-15 KR KR1020177032904A patent/KR20170138477A/ko not_active Application Discontinuation
- 2016-04-15 LT LTEP16718835.8T patent/LT3283107T/lt unknown
- 2016-04-15 MX MX2017013270A patent/MX2017013270A/es unknown
- 2016-04-15 SI SI201630887T patent/SI3283107T1/sl unknown
- 2016-04-15 TN TNP/2017/000440A patent/TN2017000440A1/en unknown
- 2016-04-15 AU AU2016249395A patent/AU2016249395B2/en active Active
- 2016-04-15 US US15/130,513 patent/US20160304607A1/en not_active Abandoned
- 2016-04-15 JP JP2017554282A patent/JP6949718B2/ja active Active
- 2016-04-15 PL PL16718835T patent/PL3283107T3/pl unknown
- 2016-04-15 HU HUE16718835A patent/HUE050894T2/hu unknown
- 2016-04-15 CA CA2982839A patent/CA2982839A1/fr active Pending
- 2016-04-15 DK DK16718835.8T patent/DK3283107T3/da active
- 2016-04-15 ES ES16718835T patent/ES2813580T3/es active Active
- 2016-04-15 EP EP20169527.7A patent/EP3738610A1/fr active Pending
- 2016-04-15 EA EA201792273A patent/EA201792273A1/ru unknown
- 2016-04-15 BR BR112017021688-4A patent/BR112017021688A2/pt active Search and Examination
- 2016-04-15 CN CN202110885081.8A patent/CN113577264A/zh active Pending
- 2016-04-15 MY MYPI2017703912A patent/MY188749A/en unknown
- 2016-04-15 RS RS20201009A patent/RS60753B1/sr unknown
- 2016-04-15 WO PCT/US2016/027913 patent/WO2016168716A1/fr active Application Filing
- 2016-04-15 SG SG11201708223QA patent/SG11201708223QA/en unknown
- 2016-04-15 PT PT167188358T patent/PT3283107T/pt unknown
- 2016-04-15 MA MA053243A patent/MA53243A/fr unknown
- 2016-04-15 CN CN201680035347.7A patent/CN107743401B/zh active Active
- 2016-04-15 EP EP16718835.8A patent/EP3283107B1/fr active Active
- 2016-04-18 TW TW111145063A patent/TW202335681A/zh unknown
- 2016-04-18 TW TW105112037A patent/TWI733664B/zh active
- 2016-04-18 TW TW110123147A patent/TWI787880B/zh active
- 2016-11-30 US US15/365,717 patent/US10512689B2/en active Active
-
2017
- 2017-09-27 PH PH12017501774A patent/PH12017501774A1/en unknown
- 2017-10-13 MX MX2022003572A patent/MX2022003572A/es unknown
- 2017-10-16 IL IL255072A patent/IL255072B/en unknown
- 2017-10-17 CL CL2017002636A patent/CL2017002636A1/es unknown
- 2017-11-10 CO CONC2017/0011536A patent/CO2017011536A2/es unknown
-
2018
- 2018-05-23 HK HK18106697.3A patent/HK1247099A1/zh unknown
-
2019
- 2019-12-20 US US16/723,854 patent/US11612654B2/en active Active
-
2020
- 2020-08-21 CY CY20201100783T patent/CY1123397T1/el unknown
- 2020-08-25 HR HRP20201334TT patent/HRP20201334T1/hr unknown
-
2021
- 2021-09-22 JP JP2021153809A patent/JP2022008479A/ja active Pending
-
2022
- 2022-01-03 IL IL289600A patent/IL289600A/en unknown
- 2022-06-10 AU AU2022204037A patent/AU2022204037A1/en active Pending
-
2023
- 2023-03-27 US US18/190,822 patent/US20240091354A1/en active Pending
- 2023-10-12 JP JP2023176705A patent/JP2024009946A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53243A (fr) | Compositions comprenant une combinaison de ipilimumab et nivolumab | |
MA44702A (fr) | Compositions de suspension à libération prolongée | |
DK3529248T3 (da) | Farmaceutiske sammensætninger | |
DK3697376T3 (da) | Sammensætning | |
DK3361870T3 (da) | Fungicidsammensætninger | |
DK3340966T3 (da) | Insulinsammensætninger med hurtig virkning | |
MA41976A (fr) | Composition lubrifiante ultra-fluide | |
DK3416996T3 (da) | Hærdelig sammensætning | |
DK3334726T3 (da) | Plinabulinsammensætninger | |
DK3250182T3 (da) | Dispergible sammensætninger | |
KR20180084875A (ko) | 정적 혼합기 | |
DK3331498T3 (da) | Nasalsammensætning | |
DK3316857T3 (da) | Multifasiske sammensætninger | |
DK3320338T3 (da) | Barrierefunktionsmålinger | |
DE102015105763A8 (de) | Korrosionsschutzzusammensetzung | |
DK3393254T3 (da) | Sammensætning | |
DK3459354T3 (da) | Glyceridsammensætning | |
DK3609464T3 (da) | Xanthohumolbaserede sammensætninger | |
DK3528791T3 (da) | Dispergible sammensætninger | |
DK3452093T3 (da) | Ophthalmiske sammensætninger | |
DK3365020T3 (da) | Hydrogelkomposit depotformulering | |
DK3337322T3 (da) | Fungicidsammensætninger | |
DK3288536T3 (da) | Sammensætninger omfattende anakinra | |
DK3256138T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam | |
BR112017016240A2 (pt) | composição |